
FDA under fire: Data discrepancies discovered in Astrazeneca approval trials
In a follow -up investigation into multimillion -dollar drug ticagrelor, The BMJ He has discovered new concerns, this time in key platelet studies used in its FDA approval. For more than a decade, Ticagrelor (Brilinta in the United States and Brilique in Europe) has been recommended for patients with acute coronary syndrome, a variety of…